A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

To join this study, you need to be at least 18 years old. You must have advanced HER2-positive stomach cancer or cancer of the gastroesophageal junction that hasn't been treated yet. Doctors need to be able to measure your cancer on scans, and a lab test must confirm that your cancer is HER2-positive.

You would not be able to join if you have had certain other cancers recently, or if your cancer has come back soon after previous treatment. You also can't have had any HER2-targeted treatments before. Some other health conditions, like serious heart problems or active bleeding in your stomach or bowel, would also prevent you from joining. The medical team will check your overall health carefully to make sure the study is right for you.

If you decide to take part, you'll be randomly assigned to one of two groups, like flipping a coin. You won't know which group you're in, and neither will your doctors usually (this is called 'double-blind'). You'll receive treatments every three weeks. This treatment will continue for as long as it helps you and you can manage any side effects, or until your doctor decides it's no longer the best option. You'll have regular appointments for check-ups, blood tests, and scans to see how you're responding and to monitor for side effects. The total length of your participation will depend on how you respond to the treatment.